Biogen

BIIB59

S&P500

$200.81arrow_drop_down0.49%-$0.99

S&P500

BIIB59

$200.81

arrow_drop_down0.49%-$0.99

S&P500

Performance History

Key Stats
Open	$202.53
Prev. Close	$201.80
EPS	7.94
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	198.55	203.24
52 Week Range	189.44	269.42

Ratios







EPS	7.94

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Biogen (BIIB)

Biogen Inc. is a leading biotechnology company that focuses on the development, manufacturing, and commercialization of therapies for neurological, autoimmune, and rare diseases. The company's primary areas of focus include multiple sclerosis (MS), Alzheimer's disease, spinal muscular atrophy (SMA), and biosimilars. Biogen's mission is to transform the lives of patients by delivering innovative treatments that address unmet medical needs.

Biogen was founded in 1978 and has since become a global leader in the biotechnology industry. The company's headquarters are located in Cambridge, Massachusetts, with additional locations throughout the United States and internationally. Biogen's team consists of talented scientists, researchers, and healthcare professionals who are dedicated to advancing the field of biotechnology and improving patient outcomes.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO: Mr. Christopher A. Viehbacher
Headquarters: Cambridge
Employees: 8725
Exchange: NASDAQ

Keep an eye on Biogen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Biogen 's (BIIB) price per share?

The current price per share for Biogen (BIIB) is $200.81. The stock has seen a price change of -$0.99 recently, indicating a -0.49% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Biogen (BIIB)?

For Biogen (BIIB), the 52-week high is $269.43, which is 34.17% from the current price. The 52-week low is $189.44, the current price is 6% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Biogen (BIIB) a growth stock?

Biogen (BIIB) has shown an average price growth of 0.41% over the past three years. It has received a score of 45 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Biogen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Biogen (BIIB) stock price performance year to date (YTD)?

As of the latest data, Biogen (BIIB) has a year-to-date price change of -24.99%. Over the past month, the stock has experienced a price change of 0.34%. Over the last three months, the change has been -13.44%. Over the past six months, the figure is -7.7%. Looking at a longer horizon, the five-year price change stands at -10.58%.

help

Is Biogen (BIIB) a profitable company?

Biogen (BIIB) has a net income of $1.16B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 74.24% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 32.5% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $9.84B, although specific revenue growth data is currently not available. The gross profit is $7.3B. Operating income is noted at $1.3B. Furthermore, the EBITDA is $2.69B.

help

What is the market capitalization of Biogen (BIIB)?

Biogen (BIIB) has a market capitalization of $29.43B. The average daily trading volume is 784.73K, indicating the stock's liquidity and investor engagement.

News

SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

BIOGEN

SPINRAZA

SPINAL MUSCULAR ATROPHY

NEUROMUSCULAR DISORDER

9/4/2024

Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder

SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology